CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 12, 2017--
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage biotechnology
company committed to developing potentially transformative gene
therapies for severe genetic diseases and cancer, today announced the
pricing of an underwritten public offering of 3,243,244 shares of its
common stock at a public offering price of $185 per share, before
underwriting discounts. In addition, bluebird bio has granted the
underwriters a 30-day option to purchase up to an additional 486,486
shares of common stock. All of the shares in the offering are to be sold
by bluebird bio.
Goldman Sachs & Co. LLC, BofA Merrill Lynch, J.P. Morgan Securities LLC
and Cowen are acting as joint book-running managers of the offering. The
offering is expected to close on or about December 15, 2017, subject to
customary closing conditions.
bluebird bio anticipates the total gross proceeds from the offering
(before deducting underwriters’ discounts and commissions and estimated
offering expenses) will be approximately $600 million, excluding any
exercise of the underwriters’ option to purchase additional shares.
The shares are being offered by bluebird bio pursuant to an
automatically effective shelf registration statement that was previously
filed with the Securities and Exchange Commission (SEC). A preliminary
prospectus supplement relating to and describing the terms of the
offering was filed with the SEC on December 11, 2017. The final
prospectus supplement relating to the offering will be filed with the
SEC and will be available on the SEC’s website at www.sec.gov.
When available, copies of the final prospectus supplement and the
accompanying prospectus relating to these securities may also be
obtained by contacting one of the following: Goldman Sachs & Co. LLC,
Attn: Prospectus Department, 200 West Street, New York, NY 10282,
telephone: (212) 902-1171, facsimile: (212) 902-9316, email: firstname.lastname@example.org;
BofA Merrill Lynch, NC1-004-03-43, 200 North College Street, 3rd floor,
Charlotte, NC 28255-0001, Attn: Prospectus Department, email: email@example.com;
J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155
Long Island Avenue, Edgewood, NY 11717, or by telephone at (866)
803-9204; or Cowen and Company, LLC, c/o Broadridge Financial Services,
1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus
Department, by telephone at (631) 274-2806 or by fax at (631) 254-7140.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of, these
securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of such state or jurisdiction.
About bluebird bio, Inc.
With its lentiviral-based gene therapies, T cell immunotherapy expertise
and gene editing capabilities, bluebird bio has built an integrated
product platform with broad potential application to severe genetic
diseases and cancer. bluebird bio's gene therapy clinical programs
include its Lenti-D™ product candidate, currently in a Phase 2/3 study,
called the Starbeam Study, for the treatment of cerebral
adrenoleukodystrophy, and its LentiGlobin® product candidate, currently
in five clinical studies for the treatment of transfusion-dependent
β-thalassemia, also known as β-thalassemia major, and severe sickle cell
disease. bluebird bio's oncology pipeline is built upon the company's
leadership in lentiviral gene delivery and T cell engineering, with a
focus on developing novel T cell-based immunotherapies, including
chimeric antigen receptor (CAR T) and T cell receptor (TCR) therapies.
bluebird bio's lead oncology programs, bb2121 and bb21217, are anti-BCMA
CAR T programs partnered with Celgene. bb2121 and bb21217 are each
currently being studied in Phase 1 trials for the treatment of
relapsed/refractory multiple myeloma. bluebird bio also has discovery
research programs utilizing megaTALs/homing endonuclease gene editing
technologies with the potential for use across the company's pipeline.
bluebird bio has operations in Cambridge, Massachusetts, Seattle,
Washington, Durham, North Carolina and Europe.
LentiGlobin and Lenti-D are trademarks of bluebird bio, Inc.
This release contains
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements regarding
the anticipated final terms, timing and completion of the proposed
offering, and bluebird bio’s existing product candidates and research
programs. Any forward-looking statements are based on management’s
current expectations of future events and are subject to a number of
risks and uncertainties that could cause actual results to differ
materially and adversely from those set forth in or implied by such
forward-looking statements. These risks and uncertainties include, but
are not limited to, risks and uncertainties related to market conditions
and satisfaction of customary closing conditions related to the proposed
public offering, that the preliminary results from our clinical trials
will not continue or be repeated in our ongoing clinical trials, the
risk of cessation or delay of any of the ongoing or planned clinical
studies and/or our development of our product candidates, the risk of a
delay in the enrollment of patients in our clinical studies, the risks
that the changes we have made in the LentiGlobin drug product
manufacturing process or the HGB-206 clinical study protocol will not
result in improved patient outcomes, risks that the current or planned
clinical studies of the LentiGlobin drug product will be insufficient to
support regulatory submissions or marketing approval in the United
States and European Union, risks that the current clinical study of
Lenti-D will be insufficient to support regulatory submissions or
marketing approval in the United States and European Union, the risk
that our collaborations, including the collaboration with Celgene, will
not continue or will not be successful, and the risk that any one or
more of our product candidates will not be successfully developed,
approved or commercialized. There can be no assurance that bluebird bio
will be able to complete the proposed public offering on the anticipated
terms, or at all. For a discussion of other risks and uncertainties, and
other important factors, any of which could cause our actual results to
differ from those contained in the forward-looking statements, see the
section entitled “Risk Factors” in our annual report on Form 10-K and
our most recent quarterly report on Form 10-Q, as well as discussions of
potential risks, uncertainties, and other important factors in our
subsequent filings with the Securities and Exchange Commission. All
information in this press release is as of the date of the release, and
bluebird bio undertakes no duty to update this information unless
required by law.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171212006490/en/
Source: bluebird bio, Inc.
Investor Relations and Media
bluebird bio, Inc.